All Title Author
Keywords Abstract

PLOS ONE  2014 

A Clinicopathological Study of Early-Stage Synchronous Bilateral Breast Cancer: A Retrospective Evaluation and Prospective Validation of Potential Risk Factors

DOI: 10.1371/journal.pone.0095185

Full-Text   Cite this paper   Add to My Lib


Background The aim of the present study was to investigate potential risk factors for synchronous bilateral breast cancer sBBC). Methods A retrospective analysis was performed of patients diagnosed and treated with operable bilateral breast cancer (BBC) between June 2007 and December 2011. Risk factors for sBBC were evaluated in this cohort and further validated in a prospective observational validation analysis of patients between January 2012 and December 2012. Patients treated with operable unilateral breast cancer during the same period were used as a control group. Results A total of 11,247 patients with primary breast cancer underwent operations at the Fudan University Shanghai Cancer Center between June 2007 and December 2012. The incidence of sBBC was 1.6%. The age at diagnosis (HR = 2.4, 95% C.I.: 1.4–4.0, p = 0.001), presence of sclerosing adenosis (HR = 11.8, 95% C.I.: 5.3–26.3, p<0.001), lobular carcinoma component involvement (HR = 5.6, 95% C.I.: 2.6–12.1, p<0.001), and family history of first-degree relatives with breast cancer (HR = 2.0, 95% C.I.: 1.1–3.4, p<0.001) were independent risk factors for sBBC. A subsequent validation study failed to confirm the significance of family history. No significant difference on survival was found between patients with early-stage sBBC and control cases. Conclusions Patients with the presence of sclerosing in the affected breast, and lobular carcinoma component involvement may be at high risk for developing sBBC. This study supports the hypothesis that the host-carcinoma biological relationship, especially for the tumor microenvironment, played a critical role in the carcinogenesis of sBBC.


[1]  Kilgore AR (1921) The incidence of cancer in the second breast: after radical removal of one breast for cancer. JAMA : the journal of the American Medical Association. 77(6): 454–7. doi: 10.1001/jama.1921.02630320038011
[2]  Abdalla I, Thisted RA, Heimann R (2006) The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer journal. 6(4): 266–72.
[3]  Bloom ND, Daluvoy RV, Ceccarelli F, Degenshein GA (1980) Bilateral mammary carcinoma; immunologic implications. New York state journal of medicine. 80(6): 908–10.
[4]  Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, et al. (2005) Genetic implications of bilateral breast cancer: a population based cohort study. The lancet oncology. 6(6): 377–82. doi: 10.1016/s1470-2045(05)70174-1
[5]  Schmid SM, Pfefferkorn C, Myrick ME, Viehl CT, Obermann E, et al. (2011) Prognosis of early-stage synchronous bilateral invasive breast cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 37(7): 623–8. doi: 10.1016/j.ejso.2011.05.006
[6]  Burns PE, Dabbs K, May C, Lees AW, Birkett LR, et al. (1984) Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Canadian Medical Association journal. 130(7): 881–6.
[7]  Beckmann KR, Buckingham J, Craft P, Dahlstrom JE, Zhang Y, et al. (2011) Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort. Breast. 20(2): 158–64. doi: 10.1016/j.breast.2010.10.004
[8]  Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, et al. (2007) Survival after bilateral breast cancer: results from a population-based study. Breast cancer research and treatment. 105(3): 347–57. doi: 10.1007/s10549-006-9455-x
[9]  Marpeau O, Ancel PY, Antoine M, Uzan S, Barranger E (2008) [Synchronous bilateral breast cancer: risk factors, diagnosis, histology and treatment]. Gynecologie, obstetrique & fertilite. 36(1): 35–44. doi: 10.1016/j.gyobfe.2007.09.021
[10]  Vuoto HD, Garcia AM, Candas GB, Zimmermann AG, Uriburu JL, et al. (2010) Bilateral breast carcinoma: clinical characteristics and its impact on survival. The breast journal. 16(6): 625–32. doi: 10.1111/j.1524-4741.2010.00976.x
[11]  Huo D, Melkonian S, Rathouz PJ, Khramtsov A, Olopade OI (2011) Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. 117(5): 907–15. doi: 10.1002/cncr.25587
[12]  Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, et al. (2012) Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer. Journal of cancer research and clinical oncology. 138(4): 705–14. doi: 10.1007/s00432-011-1141-7
[13]  Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 88(12): 2739–50. doi: 10.1002/1097-0142(20000615)88:12<2739::aid-cncr12>;2-j
[14]  Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T (2002) The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 28(4): 388–91. doi: 10.1053/ejso.2002.1266
[15]  Liang X, Li D, Geng W, Cao X, Xiao C (2013) The prognosis of synchronous and metachronous bilateral breast cancer in Chinese patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 34(2): 995–1004. doi: 10.1007/s13277-012-0636-4
[16]  Kheirelseid EA, Jumustafa H, Miller N, Curran C, Sweeney K, et al. (2011) Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast cancer research and treatment. 126(1): 131–40. doi: 10.1007/s10549-010-1057-y
[17]  Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, et al. (1984) Bilateral primary breast cancer: a prospective study of disease incidence. The British journal of surgery. 71(9): 711–4. doi: 10.1002/bjs.1800710924
[18]  Nichol AM, Yerushalmi R, Tyldesley S, Lesperance M, Bajdik CD, et al. (2011) A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(36): 4763–8. doi: 10.1200/jco.2011.35.0165
[19]  Intra M, Rotmensz N, Viale G, Mariani L, Bonanni B, et al. (2004) Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer. 101(5): 905–12. doi: 10.1002/cncr.20452
[20]  Ogura K, Horii R, Oosako T, Iwase T, Akiyama F (2013). A clinico-pathological study on cancer in sclerosing adenosis. Breast cancer. [Epub ahead of print].
[21]  Yoshida A, Hayashi N, Akiyama F, Yamauchi H, Uruno T, et al. (2012) Ductal carcinoma in situ that involves sclerosing adenosis: high frequency of bilateral breast cancer occurrence. Clinical breast cancer. 12(6): 398–403. doi: 10.1016/j.clbc.2012.08.002
[22]  Kollias J, Ellis IO, Elston CW, Blamey RW (2001) Prognostic significance of synchronous and metachronous bilateral breast cancer. World journal of surgery. 25(9): 1117–24. doi: 10.1007/bf03215857
[23]  Baykara M, Ozturk SC, Buyukberber S, Helvaci K, Ozdemir N, et al. (2012) Clinicopathological features in bilateral breast cancer. Asian Pacific journal of cancer prevention : APJCP. 13(9): 4571–5. doi: 10.7314/apjcp.2012.13.9.4571
[24]  Diaz R, Munarriz B, Santaballa A, Palomar L, Montalar J (2012) Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience. Medical oncology. 29(1): 16–24. doi: 10.1007/s12032-010-9785-8
[25]  Newman LA, Sahin AA, Cunningham JE, Bondy ML, Mirza NQ, et al. (2001) A case-control study of unilateral and bilateral breast carcinoma patients. Cancer. 91(10): 1845–53. doi: 10.1002/1097-0142(20010515)91:10<1845::aid-cncr1205>;2-z
[26]  Borg A, Haile RW, Malone KE, Capanu M, Diep A, et al. (2010) Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Human mutation. 31(3): E1200–40. doi: 10.1002/humu.21202
[27]  Tate G, Suzuki T, Endo Y, Mitsuya T (2008) A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer. Cancer genetics and cytogenetics. 184(1): 67–71. doi: 10.1016/j.cancergencyto.2008.03.013
[28]  Lorenzo Linan MA, Lorenzo Campos M, Motos Mico J, Martinez Perez C, Gumbau Puchol V (2013) Bilateral breast cancer and Peutz-Jeghers syndrome. Cirugia espanola. 91(3): 195–7. doi: 10.1016/j.cireng.2013.07.017
[29]  Kast K, Krause M, Schuler M, Friedrich K, Thamm B, et al. (2012) Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC cancer. 12: 217. doi: 10.1186/1471-2407-12-217
[30]  Tonyali O, Tufan G, Benekli M, Coskun U, Buyukberber S (2012) Synchronous bilateral breast cancer in a patient with kindler syndrome. Clinical breast cancer. 12(2): 145–6. doi: 10.1016/j.clbc.2011.09.003


comments powered by Disqus

Contact Us


微信:OALib Journal